No Data
Hunan Jiudian Pharmaceutical (300705.SZ) major shareholder Duan Lixin has completed a Shareholding of 1.13%.
Hunan Jiudian Pharmaceutical (300705.SZ) announced that the Shareholder Duan Lixin has cumulatively reduced his Shareholding by 55 shares.
Hunan Jiudian Pharmaceutical will no longer monopolize the market? Leming Luosuolofen Sodium Gel Patch has been approved, and experts predict it will accelerate the Industry review process.
① Lemin Pharmaceutical's loxoprofen sodium gel patch has officially been approved, marking it as the first to pass the consistency evaluation for approval. From this point on, the market monopoly held by Hunan Jiudian Pharmaceutical has been broken. ② Experts say this indicates new progress in the review process, marking a trend toward a unified standard for the consistency evaluation of external patches, which will result in more pharmaceutical companies being reviewed and approved.
Hunan Jiudian Pharmaceutical (300705.SZ): The controlling Shareholder Zhu Zhihong intends to increase Shareholding by 10 million to -20 million yuan in the company.
On January 17, Gelonghui reported that Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company's controlling shareholder, actual controller, and Chairman, Mr. Zhu Zhihong, plans to increase his shareholding in the company within 6 months from the date of the announcement. He intends to use his own funds to conduct purchases through the concentrated bidding trading system of the Shenzhen Securities Exchange, with a total amount to be increased no less than 10 million yuan (inclusive) and no more than 20 million yuan (inclusive).
News of suspected competitor approval causes Hunan Jiudian Pharmaceutical to "drop sharply". Is the market for Loxoprofen Sodium Gel Patch about to be reshuffled?
① A piece of news about a potential competitor's launch of loxoprofen sodium gel patches has severely impacted the stock price of Hunan Jiudian Pharmaceutical; ② Loxoprofen sodium gel patches are the Block Orders driving the revenue of Hunan Jiudian Pharmaceutical, contributing more than half of the total revenue in recent years; ③ The inclusion of patches in the national centralized procurement seems to be on the way, with related product reviews speeding up.
Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Is Hunan Jiudian Pharmaceutical (SZSE:300705) Using Too Much Debt?
Risks To Shareholder Returns Are Elevated At These Prices For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705)
